Merck Drops Development Of Cardiome’s Oral Vernakalant
This article was originally published in The Pink Sheet Daily
Higher regulatory hurdles for anti-arrhythmic drugs have pushed Merck to discontinue the development of Cardiome’s oral vernakalant.
You may also be interested in...
The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.
The New Jersey-based big pharma continues to take shots on the cardiovascular goal, even after a string of failures in the space.
Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.